TCIM
KPTI icon

TIAA CREF Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

TIAA CREF Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.39M Sell
15,893
-9,605
-38% -$1.06M ﹤0.01% 2167
2018
Q4 		$3.58M Sell
25,498
-9,239
-27% -$1.56M ﹤0.01% 1584
2018
Q3 		$8.87M Sell
34,737
-3,330
-9% -$921K 0.01% 1182
2018
Q2 		$9.7M Buy
38,067
+20,574
+118% +$5.09M 0.01% 1170
2018
Q1 		$3.52M Buy
17,493
+12,166
+228% +$2.43M ﹤0.01% 1785
2017
Q4 		$767K Sell
5,327
-718
-12% -$115K ﹤0.01% 2594
2017
Q3 		$996K Sell
6,045
-851
-12% -$122K ﹤0.01% 2518
2017
Q2 		$936K Buy
6,896
+2,288
+50% +$339K ﹤0.01% 2580
2017
Q1 		$888K Sell
4,608
-96
-2% -$15.4K ﹤0.01% 2568
2016
Q4 		$663K Sell
4,704
-498
-10% -$67.3K ﹤0.01% 2728
2016
Q3 		$759 Buy
5,202
+114
+2% +$13.7K ﹤0.01% 2672
2016
Q2 		$512K Buy
5,088
+229
+5% +$29.8K ﹤0.01% 2842
2016
Q1 		$650K Sell
4,859
-222
-4% -$24.5K ﹤0.01% 2687
2015
Q4 		$1.01M Hold
5,081
– – ﹤0.01% 2575
2015
Q3 		$802K Sell
5,081
-44
-0.9% -$11.8K ﹤0.01% 2701
2015
Q2 		$2.09M Buy
5,125
+1,675
+49% +$724K ﹤0.01% 2273
2015
Q1 		$1.58M Buy
3,450
+244
+8% +$105K ﹤0.01% 2369
2014
Q4 		$1.8M Buy
3,206
+96
+3% +$54.5K ﹤0.01% 2321
2014
Q3 		$1.63M Sell
3,110
-52
-2% -$29.3K ﹤0.01% 2356
2014
Q2 		$2.21M Buy
3,162
+1,178
+59% +$548K ﹤0.01% 2243
2014
Q1 		$919K Buy
1,984
+615
+45% +$312K ﹤0.01% 2686
2013
Q4 		$471K Buy
+1,369
New +$378K ﹤0.01% 2978

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

TIAA CREF Investment Management's KPTI Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Karyopharm Therapeutics (KPTI) stake by 38% in Q1 2019, selling an estimated $1.06M and leaving 15,893 shares worth $1.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

TIAA CREF Investment Management first reported a position in KPTI in Q4 2013 and has held it in 22 quarters since. The position peaked at $9.7M in Q2 2018. 108 funds tracked by Wall St. Rank hold KPTI as of Q1 2019.

  • TIAA CREF Investment Management held 15,893 shares of Karyopharm Therapeutics worth $1.39M as of Q1 2019.
  • TIAA CREF Investment Management sold 9,605 Karyopharm Therapeutics shares in Q1 2019, an estimated $1.06M.
  • Karyopharm Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2167 holding.
  • TIAA CREF Investment Management first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 22 quarters since.
  • TIAA CREF Investment Management's Karyopharm Therapeutics position peaked at $9.7M in Q2 2018.
  • 108 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.